A method for prediction of the immunotherapy effects to cancer patients

摘要

The present invention relates to a method for predicting the effect of immunotherapy in cancer patients, and more specifically, to a method for predicting the effect of treatment with anti-PD-1 immunoanticancer agents. Immune anti-cancer drugs are drugs that strengthen the body's own immune system and increase its resistance against cancer. Immune anti-cancer drugs complement the shortcomings of existing cancer treatments. If the first-generation chemotherapeutic agents attack cancer cells directly and the second-generation target anti-cancer drugs function to attack cancer-related genes, the immuno-cancer drugs called third-generation anticancer drugs enhance immunity To treat cancer. Kitruda and Opdivo are released as PD-1 immuno-cancer drugs, which are the most representative immuno-cancer drugs. They are used in cancer treatment in the medical field, but PD-1 immuno-cancer drugs are effective in distinguishing patients from those that are effective and those who are not. In the absence of a method, in the case of the ineffective patient group, the cost and time for the treatment of the PD-1 immuno-cancer agent are being lost. Therefore, the present invention relates to a method for predicting an immunotherapy effect in a cancer patient, and according to the method of the present invention, it is possible to distinguish between a patient group in which a PD-1 immune anticancer agent is effective and an ineffective patient group in advance. It is expected to be used.